Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Merck KGaA (DE:MRK)
XETRA:MRK
Merck KGaA (MRK) Stock Price & Analysis
73 Followers
MRK Stock Chart & Stats
Day’s Range€0 - €0
52-Week Range€132.35 - €176.25
Previous Close€152.6
Volume67.08K
Average Volume (3M)286.26K
Market Cap
€66.35B
Enterprise Value€75.18B
Total Cash (Recent Filing)€1.64B
Total Debt (Recent Filing)€10.40B
Price to Earnings (P/E)24.4
Beta0.74
Next Earnings
Aug 01, 2024EPS Estimate
€2.02Last Dividend Ex-Date
Apr 29, 2024Dividend Yield1.46%
Share Statistics
EPS (TTM)6.26
Shares Outstanding129,242,250
10 Day Avg. Volume298,235
30 Day Avg. Volume286,256
Standard Deviation0.07
R-Squared0.12
Alpha0.01
Financial Highlights & Ratios
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)N/A
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€188.44Price Target Upside23.45% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering10
Merck KGaA News
PremiumPre-Earnings
Is 0O14 a Buy, Before Earnings?
PremiumPre-Earnings
Merck KGaA (0O14) Q4 Earnings Cheat Sheet
PremiumGlobal Markets
Merck Faces Major Setback as MS Drug Fails
PremiumGlobal Markets
Do Not Miss These DAX 40 Stocks’ Earnings
PremiumPre-Earnings
Is 0O14 a Buy, Before Earnings?
Bulls Say, Bears Say
Bulls Say
Financial PerformanceHealthcare beat SFe/Cons by ~4% on top line and 9% on EBITDA, and with a guidance upgrade of low teens cc EBITDA growth to now 13%-18% is on a solid path to regain investor confidence.
Product PotentialSeveral products have the potential to be first-in-class or best-in-class, with promising results reported so far.
Stock Growth PotentialUpside to Price Target (%) 26.4 indicates potential for stock price growth.
Bears Say
Clinical TrialsMerck KGaA announced Xevinapant hit futility at the 1st interim in the Trylinx LA SCCHN Cis eligible study, and is halting all development.
Sales PerformanceMRK's LS unit €2,114 came in below our €2,357 and Consensus €2,270 estimate by 9% and 5% respectively, and 7% and 3% on EBITDA.
Stock PerformanceThere is now likely more debate on how to reinvigorate R&D at MRK's Healthcare business, which continues to weigh on shares.
---
MRK FAQ
What was Merck KGaA’s price range in the past 12 months?
Merck KGaA lowest stock price was €132.35 and its highest was €176.25 in the past 12 months.
What is Merck KGaA’s market cap?
Currently, no data Available
When is Merck KGaA’s upcoming earnings report date?
Merck KGaA’s upcoming earnings report date is Aug 01, 2024 which is in 27 days.
How were Merck KGaA’s earnings last quarter?
Merck KGaA released its earnings results on May 15, 2024. The company reported €2.06 earnings per share for the quarter, beating the consensus estimate of €1.881 by €0.179.
Is Merck KGaA overvalued?
According to Wall Street analysts Merck KGaA’s price is currently Undervalued.
Does Merck KGaA pay dividends?
Merck KGaA pays a Annually dividend of €2.2 which represents an annual dividend yield of 1.46%. See more information on Merck KGaA dividends here
What is Merck KGaA’s EPS estimate?
Merck KGaA’s EPS estimate is €2.02.
How many shares outstanding does Merck KGaA have?
Merck KGaA has 129,242,250 shares outstanding.
What happened to Merck KGaA’s price movement after its last earnings report?
Merck KGaA reported an EPS of €2.06 in its last earnings report, beating expectations of €1.881. Following the earnings report the stock price went up 4.769%.
Which hedge fund is a major shareholder of Merck KGaA?
Currently, no hedge funds are holding shares in DE:MRK
---
Merck KGaA Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
€188.44 (23.45% Upside)
€188.44 (23.45% Upside)
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
3.10%
12-Months-Change
Fundamentals
Return on Equity
10.05%
Trailing 12-Months
Asset Growth
1.78%
Trailing 12-Months
Company Description
Merck KGaA
Merck KGaA operates in three main segments: life sciences, performance materials, and healthcare. The life sciences segment provides laboratory consumables and instruments to researchers in academia and applied fields, including the biopharmaceutical industry. In its performance materials segment, the company offers specialty materials to manufacture a variety of products, such as semiconductors, flat-screen televisions, automobiles, and cosmetics. In the healthcare segment, Merck develops, manufactures, and sells branded pharmaceuticals with significant therapeutic concentrations in oncology, multiple sclerosis, and fertility. In 1995, the E. Merck KG family publicly sold part of the company, resulting in the current 30% public ownership of the firm.
---
MRK Stock 12 Month Forecast
Average Price Target
€188.44
▲(23.45% Upside)
Technical Analysis
Best Analysts Covering MRK
1 Year
1 Year Success Rate
19/26 ratings generated profit
1 Year Average Return
+15.84%
reiterated a buy rating 2 months ago
Copying Peter Spengler's trades and holding each position for 1 Year would result in 73.08% of your transactions generating a profit, with an average return of +15.84% per trade.
---